title: Demography and treatment response in patients with predominant non-erosive reflux disease or functional dyspepsia.
abstract: OBJECTIVE
  Non-erosive reflux disease (NERD) and functional dyspepsia (FD) share some common features, and the appropriateness of managing these diseases independently has been questioned. A post-hoc subgroup analysis of the LEGEND study was performed to compare demographics and treatment response between patients with NERD and patients with FD.
  
  
  METHODS
  Patients with reflux and dyspepsia symptoms who had no endoscopic evidence of mucosal breaks and/or erosions were included and divided into groups with predominant NERD (n = 1546) or FD (n = 614). Patients received lansoprazole for 4 weeks, and their symptoms were evaluated using questionnaires.
  
  
  RESULTS
  FD patients were significantly younger than NERD patients (54 vs 60 years), more likely to have a body mass index < 25 kg/m(2) (72.4% vs 67.1%), less likely to have a hiatal hernia (24.0% vs 31.2%), and more likely to feel continuous stress (54.7% vs 48.0%). After 4 weeks of treatment, > 60% of both patients reported an improvement in reflux symptoms and in most dyspepsia symptoms. The improvement rate for reflux symptoms was lower in FD patients than in NERD patients (P < 0.05), whereas the improvement rate for dyspepsia symptoms did not differ between patient groups.
  
  
  CONCLUSIONS
  Although no clinically significant differences in pathophysiology exist between NERD and FD, there are some between-group differences in demographic characteristics and improvement rates for reflux symptoms after treatment with lansoprazole. It remains to be discussed whether it is necessary to make a strict differential diagnosis between these two conditions.
authors.affiliation: Division of Gastroenterology, Department of Internal Medicine, Hyogo College of Medicine, Hyogo, Okayama, Japan.
authors.forename: Hiroto
authors.initials: H
authors.lastname: Miwa
authors.forename: Ken
authors.initials: K
authors.lastname: Haruma
authors.forename: Shigeru
authors.initials: S
authors.lastname: Sakamoto
authors.forename: Katsuyuki
authors.initials: K
authors.lastname: Sanada
authors.forename: Shinzo
authors.initials: S
authors.lastname: Hiroi
authors.forename: Yoshikazu
authors.initials: Y
authors.lastname: Kinoshita
mesh_terms: D000367:Age Factors; D000368:Aged; D015992:Body Mass Index; D004415:Dyspepsia / Q000188:drug therapy*; D005260:Female; D005764:Gastroesophageal Reflux / Q000188:drug therapy*; D006551:Hernia, Hiatal; D006801:Humans; D064747:Lansoprazole / Q000008:administration & dosage / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D011358:Product Surveillance, Postmarketing; D054328:Proton Pump Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D011795:Surveys and Questionnaires; D016896:Treatment Outcome
chemical_list: D054328:Proton Pump Inhibitors; D064747:Lansoprazole
keywords: dyspepsia; gastroesophageal reflux disease; lansoprazole